Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menü

Klinische Studien von BMS suchen
BMS-Symbol für "Studie, für die rekrutiert wird"

Recruiting

Studien-Nr. CN008-0028  |   NCT07780383

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

Zusammenfassung

  • Phase 1
  • Symbol für männliches und weibliches Geschlecht
  • 18-80
    Altersgruppe
  • 1
    Standorte
  • BMS-Symbol für "Studie, für die rekrutiert wird"
    Recruiting

Überblick

The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration

Druckmedium-alt Druckmedium
email E-Mail

Nächstgelegenes Prüfzentrum

Wichtigste Einschlusskriterien

Einschlusskriterien

Symbol für Einschlusskriterien img
  • Participants must have a BMI of 18.0 to 35.0 kg/m2.
    1. For Parts A and B: Participants must be healthy as determined by medical history, Physical Examination (PE), neurological examination, vital signs, 12-lead ECG, Columbia Suicide-Severity Rating Scale (C-SSRS), and clinical laboratory evaluations.
      1. For Part C: Participants must meet diagnostic criteria for MCI or mild AD dementia, consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) diagnostic criteria.
        1. For Part C: Participants must have an Mini Mental State Examination (MMSE) score of ≥ 20 to 28 (inclusive).
          1. For Part C: Participants must have evidence of positive plasma pTau217.

            Ausschlusskriterien

            Symbol für Ausschlusskriterien
            • For Parts A and B: Participants must not have a general history of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.
              1. For Parts A and B: Participants must not have donated or lost 500 mL blood or more within 60 days prior to study intervention administration.
                1. For Part C: Participants must not have a neurological condition that in the opinion of the investigator may be contributing to cognitive impairment aside from the AD diagnosis, including but not limited to: Parkinson's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, long COVID, or baseline intellectual disability.
                  1. For Part C: Participants must not have any current primary psychiatric diagnosis (eg, major depression, schizoaffective disorder or bipolar disorder) other than AD or symptoms (eg, hallucination or delusions).
                    Zusätzliche Informationen*
                    • Other protocol-defined Inclusion/Exclusion criteria apply.

                      Behandlungsmöglichkeiten

                      Studienarme

                      ZUGEWIESENE BEHANDLUNG

                      Studienarme

                      Experimental: Panel A1: BMS986446

                      ZUGEWIESENE BEHANDLUNG
                      • Drug: BMS-986446

                      Studienarme

                      Experimental: Panel A2: BMS986446

                      ZUGEWIESENE BEHANDLUNG
                      • Drug: BMS-986446

                      Studienarme

                      Experimental: Panel A3: BMS986446

                      ZUGEWIESENE BEHANDLUNG
                      • Drug: BMS-986446

                      Studienarme

                      Experimental: Panel B1: BMS986446

                      ZUGEWIESENE BEHANDLUNG
                      • Drug: BMS-986446

                      Studienarme

                      Experimental: Panel B2: BMS986446

                      ZUGEWIESENE BEHANDLUNG
                      • Drug: BMS-986446

                      Studienarme

                      Experimental: Panel C1: BMS986446

                      ZUGEWIESENE BEHANDLUNG
                      • Drug: BMS-986446
                      Prüfen Sie, ob eine der klinischen Studien für Sie infrage kommt
                      Kommt die Studie für Sie infrage
                      Beantworten Sie einige Fragen zu Ihrer Gesundheit, um festzustellen, ob diese Studie für Sie infrage kommt
                      Geeignete Studie
                      Wenn ihnen eine passende Studie angezeigt wird, klicken Sie auf die Studie, damit Sie die Liste der Prüfzentren angezeigt bekommen.
                      Wählen Sie einen Prüfzentrumsstandort aus
                      Wählen Sie einen Prüfzentrumsstandort aus, der für Sie günstig ist
                      Registrieren
                      Geben Sie Ihre Kontaktdaten ein, damit das Prüfzentrum mit Ihnen Kontakt aufnehmen kann.

                      Unterstützen Sie uns dabei, Ihre Nutzung der Website zu optimieren! Teilen Sie Ihr Feedback mit unserem Team bei BMS Clinical Trials, um die Nutzung der Webseite, Ihre Erfahrungen und die anderer zu verbessern. Vielen Dank!